PANDOX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.58 EUR | 0.00% |
|
-0.60% | +25.13% |
| 04-25 | Transcript : Pandox AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| 04-25 | Pandox AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Real Estate Development & Operations
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +25.13% | 3.28B | - | ||
| +27.40% | 25.58B | B- | ||
| +13.54% | 24.49B | A- | ||
| -5.18% | 24.25B | B- | ||
| -20.01% | 23.68B | B | ||
| +29.70% | 19.8B | A- | ||
| +3.54% | 19.73B | B- | ||
| -1.60% | 18.98B | A | ||
| +46.90% | 17.94B | B+ | ||
| -11.52% | 14.3B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PNDX B Stock
- POX Stock
- Ratings Pandox AB
